Amgen (AMGN) PT Raised to $230 at Oppenheimer on Enbrel Patent Confirmation
Tweet Send to a Friend
Oppenheimer analyst Jason Helfstein raised the price target on Amgen (NASDAQ: AMGN) to $230.00 (from $210.00) after the US District ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
